Purinergic signaling—particularly adenosine and ATP receptor pathways—has emerged as a promising therapeutic target in Parkinson's disease (PD). Several clinical trials have evaluated purinergic receptor modulators, with the adenosine A2A receptor antagonists showing the most advanced clinical development.
Mechanism: Selective A2A receptor antagonist
Trial History:
Key Trial Data:
Clinical Impact:
Istradefylline represents the first FDA-approved purinergic-based therapy for PD, validating A2A receptor targeting as a therapeutic strategy.
Company: Biotie/Acorda Therapeutics
Phase: Phase 3 (discontinued)
Outcome: Discontinued in 2017 due to safety concerns (reversible agranulocytosis)
Lessons Learned: Emphasizes the importance of immune monitoring in purinergic drug development
Company: Schering-Plough/Merck
Phase: Phase 3
Outcome: Failed to meet primary endpoints in pivotal trials (2013)
Analysis: Showed no significant improvement over placebo in reducing OFF time
Company: Biogen
Phase: Phase 2
Outcome: Completed but not advanced to Phase 3
Company: Janssen
Phase: Phase 1 (completed)
Target: P2X7 receptor on microglia
Rationale: Block neuroinflammation driven by NLRP3 inflammasome activation
Status: Phase 1 completed in healthy volunteers; no Phase 2 PD trial initiated as of 2025
Company: AstraZeneca
Phase: Phase 2 (rheumatoid arthritis)
Note: Not developed specifically for PD but serves as proof-of-concept for P2X7 targeting
Status: Preclinical
Challenge: Blood-brain barrier penetration remains a key hurdle
Rationale: Synergistic effect through different mechanisms
Evidence: Clinical trials consistently show enhanced OFF time reduction with combination therapy
Current Practice: Istradefylline approved as adjunct to L-DOPA/carbidopa
Title: "CSF Purinergic Biomarkers in Early Parkinson's Disease"
Objective: Validate ATP/ADP/adenosine levels as diagnostic biomarkers
Endpoints:
Status: Proposed/placeholder
| Biomarker | PD vs. Control | Clinical Utility |
|---|---|---|
| ATP | Elevated | Diagnostic |
| ADP | Elevated | Diagnostic |
| Adenosine | Variable | Unclear |
| ATP/ADP ratio | Elevated | Promising |
Inclusion Criteria:
Exclusion Criteria:
Motor Outcomes:
Non-Motor Outcomes:
Biomarker Endpoints: